Ptc Therapeutics (PTCT) Cash from Investing Activities (2012 - 2026)

Ptc Therapeutics' Cash from Investing Activities history runs 15 years deep, the most recent figure standing at -$93.7 million for Q1 2026.

• On a quarterly basis, Cash from Investing Activities rose 49.16% year-over-year to -$93.7 million in Q1 2026; TTM through Mar 2026 was -$771.4 million, a 2955.38% decrease from a year earlier, with the FY2025 full-year figure at -$862.0 million, down 2050.98% from the prior year.
• Cash from Investing Activities eased to -$93.7 million in Q1 2026 per PTCT's latest filing, from $34.0 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $267.7 million in Q4 2024 and bottomed at -$422.0 million in Q2 2025.
• The 5-year median for Cash from Investing Activities is -$29.6 million (2023), against an average of -$46.9 million.
• Across the five-year window, Cash from Investing Activities soared 383.54% in 2024 and slumped 578.67% in 2025, its largest moves.
• Year by year, Cash from Investing Activities stood at $32.4 million in 2022, then sank by 391.06% to -$94.4 million in 2023, then surged by 383.54% to $267.7 million in 2024, then plunged by 87.3% to $34.0 million in 2025, then sank by 375.63% to -$93.7 million in 2026.
• Per Business Quant, the three latest PTCT Cash from Investing Activities figures stand at -$93.7 million (Q1 2026), $34.0 million (Q4 2025), and -$289.6 million (Q3 2025).